During 2025, several of our portfolio companies – AnaCardio, Dilafor, BOOST Pharma, SVF Vaccines and Umecrine Cognition – reached important milestones in clinical development, capitalisation and partnerships. Taken together, the progress confirms the strength of KDventures’ strategy and the portfolio’s long-term value creation potential.
News Published
Don’t miss the annual report for 2025
2025 was filled with progress in clinical development and strategic collaborations across our portfolio companies. During the latter part of the year, we laid the groundwork for the financing round that was completed at the beginning of 2026, with strong interest from external investors and a broadened shareholder base.
